85
Participants
Start Date
September 29, 2015
Primary Completion Date
December 28, 2016
Study Completion Date
December 28, 2016
JBT-101 (lenabasum)
Subjects will receive JBT-101 1 mg qd or JBT-101 5 mg qd on Days 1-28. Subjects will receive either JBT-101 20 mg q am (with placebo q pm) or JBT-101 20 mg twice a day on Days 29-84.
Placebo
Subjects will receive placebo once a day on Days 1-28, placebo q pm on Days 29-84 (with JBT-101 20 mg q am), or placebo bid on Days 29-84.
Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan
UNI Essen Abt.Pneumologie, Essen
Christiane Herzog CF-Zentrum Frankfurt am Main, Frankfurt am Main
University of Arkansas for Medical Sciences, Little Rock
Long Beach Memorial Medical Center/Miller Children's and Women's Hospital, Long Beach
National Jewish Health, Denver
Boston Children's Hospital, Boston
Massachusetts General Hospital, Boston
North Shore LIJ Health System, New Hyde Park
New York Medical College, Valhalla
University Hospitals Cleveland Medical Center, Cleveland
Medical University of South Carolina, Charleston
The University of Texas Southwestern Medical Center, Dallas
Texas Children's Hospital Clinical Care Center, Houston
Hôpital Erasme, Brussels
Hôpital Arnaud de Villeneuve, Montpellier
Institution Hôpital Pasteur, Nice
Centre de Perharidy, Roscoff
AOUI di Verona - Ospedale Borgo Trento UOC Fibrosi Cistica, Verona
Belfast City Hospital, Belfast
Queen Elizabeth University Hospital, Glasgow
Rutgers Robert-Wood Johnson Medical School, New Brunswick
Szpital Dziecięcy Polanki im. Macieja Płażyńskiego w Gdańsku Spółka z o.o. Poradnia Leczenia Mukowiscydozy, Gdansk
Sanatorium Cassia-Villa Medica s.c, Rabka-Zdrój
Podkarpacki Ośrodek Pulmunologii i Alergologii, Rzeszów
Instytut Gruźlicy i Chorób Płuc I Klinika Chorób Płuc, Warsaw
Lead Sponsor
Corbus Pharmaceuticals Inc.
INDUSTRY